首页 | 本学科首页   官方微博 | 高级检索  
     

曲普瑞林对特发性中枢性性早熟女童体质量指数及终身高的影响
引用本文:冯海英,张蕾,周燕,黄邀. 曲普瑞林对特发性中枢性性早熟女童体质量指数及终身高的影响[J]. 中国基层医药, 2014, 0(7): 979-981
作者姓名:冯海英  张蕾  周燕  黄邀
作者单位:[1]台州恩泽医疗集团台州市中心医院儿科, 浙江省台州318000 [2] 台州恩泽医疗集团台州医院儿科, 浙江省台州318000
基金项目:浙江省台州市科技计划项目(11ky21)
摘    要:目的:观察促性腺激素类似物( GnRHa)曲谱瑞林对特发性中枢性性早熟( ICPP)女童体质量指数(BMI)及最终成年身高(FAH)的影响。方法总结及追踪回访120例ICPP女童。62例ICPP女童接受曲普瑞林治疗(治疗组),观察治疗后6、12、18、24、36个月的骨龄(BA)、生长速率(GV)、BMI、预测身高(PAH),终身高及达终身高时的BMI。未治疗组(对照组)也观察相关的指标如BMI及终身高。结果曲普瑞林治疗后骨龄的增长低于年龄的增长,预测身高随着治疗疗程的增长有所提升。治疗后12、18、24、36个月PAH分别为(153.4±7.1)cm、(154.6±6.2)cm、(155.7±4.7)cm、(156.9±5.9)cm,与对照组比较差异均有统计学意义(t=2.23、2.67、3.01、2.88,均P <0.01);BMI 分别为(16.37±1.41) kg/m2、(16.99±1.21) kg/m2、(17.17±1.38)kg/m2、(17.02±1.42)kg/m2,与对照组比较差异均无统计学意义(t=0.69、1.28、0.89、1.11,均P>0.05)。治疗组和对照组终身高分别为(158.2±3.9) cm、(153.7±2.8) cm,两组差异有统计学意义(t=3.04,P<0.01)。达终身高时两组BMI分别为(19.1±1.9)kg/m2、(18.7±1.8)kg/m2,两组差异无统计学意义( t=0.35,P>0.05)。结论曲普瑞林能有效抑制ICPP的性征发育、骨龄增长、改善成年终身高,对BMI无明显影响。

关 键 词:曲普瑞林  特发性中枢性性早熟  体质量指数  成年终身高

Observation of body mass index and final adult height of triptorelin on idiopathic central precocious puberty
Feng Haiying,Zhang Lei,Zhou Yan,Huang Yao. Observation of body mass index and final adult height of triptorelin on idiopathic central precocious puberty[J]. Chinese Journal of Primary Medicine and Pharmacy, 2014, 0(7): 979-981
Authors:Feng Haiying  Zhang Lei  Zhou Yan  Huang Yao
Affiliation:Feng Haiying, Zhang Lei, Zhou Yan, Huang Yao
Abstract:Objective To observe the gonadotropin analogue ( GnRHa) Triptorelin of idiopathic central pre-cocious puberty(ICPP) girls′body mass index(BMI) and final adult height(FAH).Methods 120 patients with idi-opathic central precocious puberty cases were summarized and track the return visit ,which.of 62 cases with ICPP girls Triptorelin treatment,6,12,18,24,36 months of observation and treatment of bone age (BA),the growth rate(GV), BMI,predicted height ( PAH) ,and life-long high and up to lifelong high BMI .The untreated group was also observed the relevant indicators such as BMI ,and lifelong.Results After treatment,the increase in BA was less than that in age.The PAH has improved with the growth of the treatment regimens .After treatment PAH 12,18,24,36 months PAH respectively[(153.4 ±7.1)cm,(154.6 ±6.2)cm,(155.7 ±4.7)cm,(156.9 ±5.9) cm], both were statisti-cally significant(t=2.23,2.67,3.01,2.88,all P<0.01); BMI [(16.37 ±1.41)kg/m2,(16.99 ±1.21)kg/m2, (17.17 ±1.38)kg/m2,(17.02 ±1.42)kg/m2] between the two were not statistically significant (t=0.69,1.28, 0.89,1.11,all P>0.05).Lifelong treatment and control groups,respectively[(158.2 ±3.9)cm,(153.7 ±2.8) cm],and between the two there is a statistically significant (t=3.04,P<0.01).BMI were up to lifelong[(19.1 ± 1.9)kg/m2,(18.7 ±1.8) kg/m2] between the two was not statistically significant (t =0.35,P >0.05). Conclusion Triptorelin can effectively suppress idiopathic central precocious sexual characteristics and bone age growth and improve adult height .There is no significant effect on the BMI .
Keywords:Triptorelin  Idiopathic central precocious puberty  Body mass Index  Final adult height
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号